Evidence overview
Glutathione
Glutathione is the body's principal intracellular antioxidant and a frequent target of supplement marketing, but the evidence base for oral supplementation is unusually thin given the popularity of the supplement. Most rigorous glutathione research is conducted via the precursor N-acetylcysteine (NAC) or via intravenous administration in clinical settings, not via the oral capsule or powder forms most consumers encounter.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Tripeptide of glutamate, cysteine, and glycine; the principal endogenous intracellular antioxidant. Detoxifies reactive oxygen...
Study coverage
Study coverage by goal
PubMed counts for Glutathione grouped by the goal each study targets.
Evidence overview is temporarily unavailable for Glutathione.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
Glutathione is studied in several distinct supplemental forms whose bioavailability differs dramatically: oral capsules and powders (low absorption, with most of the dose hydrolyzed in the gut before reaching cells), liposomal preparations (marketed as a workaround, with mixed clinical data), sublingual and topical forms (limited research), and intravenous glutathione (clinical-only, primarily in hepatology, cosmetic, and oncology contexts). The field continues to debate whether oral glutathione meaningfully raises intracellular GSH or whether observed benefits are mediated entirely through systemic precursors.
The outcome dimensions most often studied in the oral-supplement literature are oxidative stress biomarkers (lipid peroxidation, 8-OHdG, serum GSH-to-GSSG ratio), skin tone and pigmentation (a substantial cosmetic-medicine literature, primarily from Asian centers), liver function in fatty liver disease, and immune markers. Notably, much of what the public reads as 'glutathione research' is actually research on N-acetylcysteine (NAC) - the cysteine-donating precursor - whose evidence base for psychiatric, respiratory, and hepatic indications is markedly stronger than oral glutathione's own.
Demographically, the cosmetic-pigmentation literature concentrates on Asian-population trials; the systemic-oxidative-stress literature is small and methodologically heterogeneous. Trials on oral glutathione in healthy adults are short and small. The literature's most consistent finding is the bioavailability challenge itself, which several decades of formulation work have only partially addressed.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Oral glutathione is generally well-tolerated at typical supplemental doses. Reported adverse events are mild and infrequent: gastrointestinal discomfort, occasional cramping, and rare allergic reactions. No established tolerable upper limit. Intravenous glutathione (clinical setting only) has been associated with rare cases of toxic epidermal necrolysis and Stevens-Johnson syndrome, particularly when used cosmetically for skin lightening - the FDA has issued warnings about non-medical IV glutathione use. Drug interactions are poorly characterized; theoretical interactions with chemotherapy (antioxidant interference) and with acetaminophen detoxification have been raised. People considering IV glutathione for cosmetic purposes should be aware of the published safety concerns.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the glutathione literature at a general level. The most important limitation specific to glutathione is bioavailability: oral supplementation may not meaningfully raise intracellular GSH, and raising endogenous glutathione is more commonly studied via the precursor N-acetylcysteine (NAC), whose clinical literature is substantially more developed than that of oral glutathione. If your goal is to raise systemic glutathione, the personalized report can address whether NAC or another precursor approach is more evidence-aligned for your specific case.
Personalized to you
Get a personalized Glutathione report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Glutathione materially updates. No account required.